Lupin gets UK MHRA approval for Goa facility
New Delhi: Pharma major Lupin announced that it has received approval from the UK health regulator for its Goa facility.
Lupin in a regulatory filing said, "it has received approval from UK MHRA (United Kingdom's Medicines and Healthcare products Regulatory Agency) for its Goa facility.
The unit was inspected by UK MHRA in March 2018 and there were no critical or major observations cited, it added.
Commenting on the development, Nilesh Gupta, Managing Director – Lupin said, “The outcome of this inspection is a positive and encouraging sign for us, and is a testament to our commitment to maintain global manufacturing standards and best practices. This approval from UK MHRA is a significant development for our Goa plant.”
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd